Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of VX-509 in active rheumatoid arthritis on stable DMARDs
2012-003439-41Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of decernotinib in rheumatoid arthritis (RA) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: ACR20 CRP response. Started Dec 2012; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003439-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003439-41.